Next generation antisense treatment for eye and inflammatory diseases as well as cancer.
Total raised: $25.306584M
Investors 2
| Date | Name | Website |
| - | MIG AG | mig.ag |
| - | S-REFIT | s-refit.de |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 24.04.2014 | - | $7.607108M | - | fiercebiot... |
| 07.01.2014 | - | $17.699476... | - | finsmes.co... |
Mentions in press and media 5
| Date | Title | Description | Category | Author | Source |
| 04.05.2016 | Isarna Pre... | — Preliminary Data Shows That ... | - | Business W... | venturebea... |
| 25.04.2014 | Isarna sna... | After shifting its focus to im... | Venture Ca... | - | fiercebiot... |
| 24.04.2014 | Isarna The... | Isarna Therapeutics GmbH, a Mu... | funding G... | - | finsmes.co... |
| 24.04.2014 | Isarna The... | MUNICH–(BUSINESS WIRE)–April 2... | - | Business W... | venturebea... |
| 07.01.2014 | Isarna The... | Isarna Therapeutics GmbH, a Mu... | funding G... | - | finsmes.co... |